Jump to content

Revefenacin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
New ATC code; drugbox additions; navbox
consistent citation formatting
Line 55: Line 55:
}}
}}


'''Revefenacin''' (trade name '''Yupelri''') is a pharmaceutical drug for the treatment of [[chronic obstructive pulmonary disease]] (COPD). It was approved for use in the United States in 2018.<ref>{{cite press release | url = http://newsroom.mylan.com/2018-11-09-Theravance-Biopharma-and-Mylan-Receive-FDA-Approval-for-YUPELRI-TM-revefenacin-in-Adults-with-Chronic-Obstructive-Pulmonary-Disease | title = Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease | publisher = Mylan | date = November 9, 2018}}</ref> It was [[drug development|developed]] by Theravance Biopharma and is marketed by [[Mylan]]. Revefenacin is [[Pharmaceutical formulation|formulated]] as a solution that is [[Nebulizer|nebulized]] and inhaled.<ref>{{Cite journal | doi = 10.1007/s40265-018-1036-x| pmid = 30560478| title = Revefenacin: First Global Approval| journal = Drugs| year = 2018| last1 = Heo| first1 = Young-A| pmc = 6445810}}</ref>
'''Revefenacin''' (trade name '''Yupelri''') is a pharmaceutical drug for the treatment of [[chronic obstructive pulmonary disease]] (COPD). It was approved for use in the United States in 2018.<ref>{{cite press release | url = http://newsroom.mylan.com/2018-11-09-Theravance-Biopharma-and-Mylan-Receive-FDA-Approval-for-YUPELRI-TM-revefenacin-in-Adults-with-Chronic-Obstructive-Pulmonary-Disease | title = Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease | publisher = Mylan | date = November 9, 2018}}</ref> It was [[drug development|developed]] by Theravance Biopharma and is marketed by [[Mylan]]. Revefenacin is [[Pharmaceutical formulation|formulated]] as a solution that is [[Nebulizer|nebulized]] and inhaled.<ref>{{cite journal | vauthors = Heo YA | title = Revefenacin: First Global Approval | journal = Drugs | volume = 79 | issue = 1 | pages = 85–91 | date = January 2019 | pmid = 30560478 | pmc = 6445810 | doi = 10.1007/s40265-018-1036-x }}</ref>


Revefenacin is a [[bronchodilator]] that exerts its effect as a long-acting [[muscarinic antagonist]].<ref>{{Cite journal | doi = 10.1016/j.chest.2018.08.665| title = Efficacy of Revefenacin, A Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients with Markers of More Severe Disease| journal = Chest| volume = 154| issue = 4| pages = 736A–737A| year = 2018| last1 = Donohue| first1 = James| last2 = Kerwin| first2 = Edward| last3 = Barnes| first3 = Chris| last4 = Moran| first4 = Edmund| last5 = Haumann| first5 = Brett| last6 = Pendyala| first6 = Srikanth| last7 = Crater| first7 = Glenn}}</ref>
Revefenacin is a [[bronchodilator]] that exerts its effect as a long-acting [[muscarinic antagonist]].<ref name="pmid32393215">{{cite journal | vauthors = Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD | title = Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis | journal = BMC Pulmonary Medicine | volume = 20 | issue = 1 | pages = 134 | date = May 2020 | pmid = 32393215 | pmc = 7216337 | doi = 10.1186/s12890-020-1156-4 }}</ref>


==References==
== References ==
{{reflist}}
{{reflist}}


Revision as of 09:17, 2 August 2020

Revefenacin
Clinical data
Trade namesYupelri
AHFS/Drugs.comyupelri
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)
  • CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
  • InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
  • Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]

References

  1. ^ "Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. November 9, 2018.
  2. ^ Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
  3. ^ Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1): 134. doi:10.1186/s12890-020-1156-4. PMC 7216337. PMID 32393215.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Revefenacin&oldid=970776704"